Clinical use of cabergoline as primary and adjunctive treatment for acromegaly

European Journal of Endocrinology

Volumn 159, Issue 5, 2008, Pages 541-545

  Moyes, V J ^a   Metcalfe, K A ^b   Drake, William M ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b Southend Hospital   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CABERGOLINE; GROWTH HORMONE; SOMATOMEDIN C;

ACROMEGALY; ADENOHYPOPHYSIS; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDICATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTERNAL BEAM RADIOTHERAPY; FEMALE; GROWTH HORMONE BLOOD LEVEL; HORMONE DETERMINATION; HUMAN; HUMAN TISSUE; HYPERPROLACTINEMIA; HYPOPHYSIS TUMOR; MALE; MEDICAL AUDIT; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; REFERENCE VALUE; SELLA TURCICA; TRANSSPHENOIDAL HYPOPHYSECTOMY; TREATMENT DURATION;

ACROMEGALY; ADENOMA; ADULT; AGED; AGED, 80 AND OVER; DOPAMINE AGONISTS; ERGOLINES; FEMALE; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MAGNETIC RESONANCE IMAGING; MALE; MEDICAL AUDIT; MIDDLE AGED; PITUITARY GLAND; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 56749098338     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-08-0306     Document Type: Article

References (23)

1. Wright AD, Hill DM, Lowy C & Fraser TR. Mortality in acromegaly. Quarterly Journal of Medicine 1970 39 1-16.
2. Alexander L, Appleton D, Hall R, Ross WM & Wilkinson R. Epidemiology of acromegaly in the Newcastle region. Clinical Endocrinology 1980 12 71-79.
3. Bates AS, Van't Hoff W, Jones JM & Clayton RN. An audit of outcome of treatment in acromegaly. Quarterly Journal of Medicine 1993 86 293-299.
4. Fahlbusch R, Honegger J & Buchfelder M. Surgical management of acromegaly. Endocrinology and Metabolism Clinics of North America 1992 21 669-692.
5. Swearingen B, Barker FG II, Katznelson L, Biller BM, Grinspoon S, Klibanski A, Moayeri N, Black PM & Zervas NT. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. Journal of Clinical Endocrinology and Metabolism 1998 83 3419-3426.
6. Freda PU, Wardlaw SL & Post KD. Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly. Journal of Neurosurgery 1998 89 353-358.
7. Sheaves R, Jenkins P, Blackburn P, Huneidi AH, Afshar F, Medbak S, Grossman AB, Besser GM & Wass JA. Outcome of transsphenoidal surgery for acromegaly using strict criteria for surgical cure. Clinical Endocrinology 1996 45 407-413.
8. Long H, Beauregard H, Somma M, Comtois R, Serri O & Hardy J. Surgical outcome after repeated transsphenoidal surgery in acromegaly. Journal of Neurosurgery 1996 85 239-247.
9. Plowman PN. Radiotherapy for pituitary tumours. Baillière's Clinical Endocrinology and Metabolism 1995 9 407-420.
10. Verhelst JA, Pedroncelli AM, Abs R, Montini M, Vandeweghe MV Albani G, Maiter D, Pagani MD, Legros JJ, Gianola D, Bex M, Poppe K, Mockel J & Pagani G. Slow-release lanreotide in the treatment of acromegaly: a study in 66 patients. European Journal of Endocrinology 2000 143 577-584.
11. Chanson P, Leselbaum A, Blumberg J & Schaison G. Efficacy and tolerability of the long-acting somatostatin analog lanreotide in acromegaly. A 12-month multicenter study of 58 acromegalic patients. French Multicenter Study Group on Lanreotide in acromegaly. Pituitary 2000 2 269-276.
12. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser GM, Scarlett JA, Thorner MO, Parkinson C, Klibanski A, Powell JS, Barkan AL, Sheppard MC, Malsonado M, Rose DR, Clemmons DR, Johannsson G, Bengtsson BA, Stavrou S, Kleinberg DL, Cook DM, Phillips LS, Bidlingmaier M, Strasburger CJ, Hackett S, Zib K, Bennett WF & Davis RJ. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. New England Journal of Medicine 2000 342 1171-1177.
13. van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, Klibanski A, Herman-Bonert V, Melmed S, Vance ML, Freda PU, Stewart PM, Friend KE, Clemmons DR, Johannsson G, Stavrou S, Cook DM, Phillips LS, Strasburger CJ, Hackett S, Zib KA, Davis RJ, Scarlett JA & Thorner MO. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001 358 1754-1759.
14. Abs R, Verhelst J, Maiter D, Van Acker K, Nobels F, Coolens JL, Mahler C & Beckers A. Cabergoline in the treatment of acromegaly: a study in 64 patients. Journal of Clinical Endocrinology and Metabolism 1998 83 374-378.
15. Alexopoulou O, Bex M, Abs R, T'sjoen G, Vellieniers B & Maiter D. Divergence between growth hormone and insulin-like growth factor-I concentrations in the follow-up of acromegaly. Journal of Clinical Endocrinology and Metabolism 2008 93 1324-1330.
16. Thorner MO, Chait A, Aitken M, Beaker G, Bloom SR, Mortimer CH, Sanders P, Mason AS & Besser GM. Bromocriptine treatment of acromegaly. BMJ 1975 1 299-303.
17. Cozzi R, Attanasio R, Lodrini S & Lasio G. Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status. Clinical Endocrinology 2004 61 209-215.
18. Colao A, Ferone D, Marzullo P, Di Sarno A, Cerbone G, Sarnacchiaro F. Cirillo S, Merola B & Lomardi G. Effect of different dopaminergic agents in the treatment of acromegaly. Journal of Clinical Endocrinology and Metabolism 1997 82 518-523.
19. Ferrari CI, Abs R, Bevan JS, Brabant G, Ciccarelli E,, Motta T, Mucci M, Muratori M, Musatti L, Verbessem G & Scarlon MF. Treatment of macroprolactinoma with cabergoline: a study of 85 patients. Clinical Endocrinology 1997 46 409-413.
20. Jackson SN, Fowler J & Howlett TA. Cabergoline treatment of acromegaly: a preliminary dose finding study. Clinical Endocrinology 1997 46 745-749.
21. Selvarajah D, Webster J, Ross R & Newell-Price J. Effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly. European Journal of Endocrinology 2005 152 569-574.
22. Gatta B, Han DH, Catargi B, Roger P & Tabarin A. Re-evaluation of the efficacy of the association of cabergoline to somatostatin analogues in acromegalic patients. Clinical Endocrinology 2005 63 477-478.
23. Schade R, Andersohn F, Suissa S, Haverkamp W & Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. New England Journal of Medicine 2007 356 29-38.